Website search
The global demand for targeted, effective treatments for a wide range of diseases has led to significant growth in the number of antibody drugs. A third of all new medicines under development involve an antibody therapy. They account for more than 100 licensed treatments for cancer, autoimmune disease and blood clotting, and over 200 were in development during the COVID-19 pandemic to tackle the virus.
For 30 years, UCLB has been supporting and developing innovations that emerge from the world-leading research at UCL. As the technology transfer space continues to develop, we’re excited to see what the next three decades hold.
E-lucid is a software solution that takes the pain out of non-exclusive licensing for all the involved parties, reducing barriers for licensees and freeing up time to focus on more interesting challenges.
By UCLB’s Anne Lane, for Research Professional News. The government’s Innovation Strategy, published in July, sets out its ambitions for the UK to “lead the future by creating it”. This involves generating the technology giants of the future and helping everyday businesses to become more innovative. Many of the candidates for such companies will emerge
WPP, the world’s largest advertising and creative group headquartered in London, has announced the acquisition of Satalia Ltd, an award-winning provider of artificial intelligence (AI) solutions.
Apollo Therapeutics, a unique collaboration between three leading universities (University College London, Imperial College and University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson) set up in late 2015 has received £100m in investment to further develop and translate early-stage science into clinical development for patient benefit. In order to
A major breakthrough in hydrogen fuel cell technology is powering an exciting new era in clean energy. UCLB spinout Bramble Energy are using low-cost materials and manufacturing processes to create a highly portable and flexible range of battery products. With applications across multiple industries, Bramble’s advances are helping to bring sustainable energy goals in sight.
All Study Participants in 6e13 vg/kg and 4e13 vg/kg Dose Cohorts Remain off Factor VIII Prophylactic Therapy 95% Reductions in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annualized Factor VIII Usage Through Year 5 in 6e13 vg/kg Dose Cohort 92% Reductions in Mean ABR and 95% Reduction in Mean Annualized Factor VIII